The novel cereblon-modulating agent avadomide demonstrated preliminary clinical efficacy among patients with relapsed or refractory diffuse large B-cell lymphoma, according to results of a phase 1 study published in Blood.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.
